BusinessNeos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare ConferenceBy Nasdaq OMXFeb 16, 2017, 12:30 PM UTC
BusinessNeos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHDBy Nasdaq OMXDec 20, 2016, 12:30 PM UTC
BusinessNeos Therapeutics to Present at BMO Prescription for Success Healthcare ConferenceBy Nasdaq OMXDec 7, 2016, 1:00 PM UTC
BusinessNeos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHDBy Nasdaq OMXNov 17, 2016, 1:00 PM UTC
